BRAF and thyroid cancer: The results of the present study show that the selective BRAF-inhibitor, PLX4720, inhibits the basal and the TNFα-stimulated secretion of CXCL8 in BRAFV600E mutated thyroid cancer cell lines (BCPAP, 8305C and 8505C).